keyword
MENU ▼
Read by QxMD icon Read
search

Gemcitabine pulmonary toxicity

keyword
https://www.readbyqxmd.com/read/27733144/successful-treatment-of-gemcitabine-induced-acute-interstitial-pneumonia-with-imatinib-mesylate-a-case-report
#1
Elisabetta Fenocchio, Ilaria Depetris, Delia Campanella, Lucia Garetto, Fabrizio Carnevale Schianca, Danilo Galizia, Giovanni Grignani, Massimo Aglietta, Francesco Leone
BACKGROUND: Gemcitabine is currently the standard chemotherapy for the adjuvant treatment of pancreatic cancer. This chemotherapeutic agent is generally well-tolerated, myelosuppression and gastrointestinal toxicity being common side effects. Nevertheless, gemcitabine-induced pulmonary toxicity has been rarely reported. Despite its low incidence, the spectrum of pulmonary injury is wide, including potentially fatal conditions. We report a case of acute interstitial pneumonia related to gemcitabine, completely solved with Imatinib Mesylate (IM)...
October 12, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27064056/gemcitabine-fludarabine-and-melphalan-for-reduced-intensity-conditioning-and-allogeneic-stem-cell%C3%A2-transplantation-for-relapsed-and-refractory-hodgkin%C3%A2-lymphoma
#2
Paolo Anderlini, Rima M Saliba, Celina Ledesma, Tamera Plair, Amin M Alousi, Chitra M Hosing, Issa F Khouri, Yago Nieto, Uday R Popat, Elizabeth J Shpall, Michelle A Fanale, Frederick B Hagemeister, Yasuhiro Oki, Saatva Neelapu, Jorge E Romaguera, Anas Younes, Richard E Champlin
Forty patients (median age, 31 years; range, 20 to 63) with Hodgkin lymphoma underwent an allogeneic stem cell transplant with the gemcitabine-fludarabine-melphalan reduced-intensity conditioning regimen. Thirty-one patients (77%) had undergone a prior autologous stem cell transplant, with a median time to progression after transplant of 6 months (range, 1 to 68). Disease status at transplant was complete remission/complete remission, undetermined (n = 23; 57%), partial remission (n = 14; 35%), and other (n = 3; 8%)...
July 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/26500758/cytotoxic-and-targeted-therapy-for-treatment-of-pseudomyogenic-hemangioendothelioma
#3
Jason Joseph, Wei-Lien Wang, Madhavi Patnana, Naveen Ramesh, Robert Benjamin, Shreyaskumar Patel, Vinod Ravi
Pseudomyogenic hemangioendothelioma (PMH) is a recently described, indolent vascular tumor that usually presents in the distal extremities. PMH typically has a multi-focal presentation and can involve several tissue planes including the dermis, subcutis, muscle, and bone. This soft tissue tumor predominantly affects men between 20 and 50 years of age. PMH tumors typically are resected but frequently recur locally; thus, more efficacious treatment options are needed. Herein, we report two cases of patients with PMH who were treated with systemic therapy...
2015: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/26453787/inhalable-liposomal-dry-powder-of-gemcitabine-hcl-formulation-in-vitro-characterization-and-in-vivo-studies
#4
Manit Gandhi, Tosha Pandya, Ravi Gandhi, Sagar Patel, Rajashree Mashru, Ambikanandan Misra, Hemal Tandel
Pulmonary drug delivery system facilitates local instillation of anticancer drugs to lungs which has proven to be pioneering approach for treatment of lung cancer. This approach led the groundwork for delivering liposomal formulation directly to lungs. Gemcitabine-HCl is currently considered as most effective drug for management of lung cancer. However, its application is limited owing to its metabolism by enzymes present in plasma resulting in reduced efficacy and higher toxicity. In present study, lyophilisation technique was used to convert liposomes into dry powder inhaler, which was formulated using emulsification solvent evaporation technique...
December 30, 2015: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/26380562/gemcitabine-induced-pulmonary-toxicity-a-case-report-of-pulmonary-veno-occlusive-disease
#5
Célia Turco, Marine Jary, Stefano Kim, Mélanie Moltenis, Bruno Degano, Philippe Manzoni, Thierry Nguyen, Bruno Genet, Marie-Blanche Valnet Rabier, Bruno Heyd, Christophe Borg
INTRODUCTION: Gemcitabine is a chemotherapeutic agent frequently used by for the treatment of several malignancies both in the adjuvant and metastatic setting. Although myelosuppression is the most adverse event of this therapy, gemcitabine might induce severe pulmonary toxicities. We describe a case of pulmonary veno-occlusive disease (PVOD) related to gemcitabine. CASE PRESENTATION: The patient was an 83-year-old man with a metastatic pancreatic cancer who was treated by gemcitabine as first-line therapy...
2015: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/26199392/bevacizumab-high-dose-chemotherapy-with-autologous-stem-cell-transplant-for-poor-risk-relapsed-or-refractory-germ-cell-tumors
#6
Y Nieto, S-M Tu, R Bassett, R B Jones, A M Gulbis, N Tannir, A Kingham, C Ledesma, K Margolin, L Holmberg, R Champlin, L Pagliaro
BACKGROUND: High-dose chemotherapy (HDC) using sequential cycles of carboplatin/etoposide is curative for relapsed germ-cell tumors (GCT). However, outcomes of high-risk patients in advanced relapse remain poor. We previously developed a new HDC regimen combining infusional gemcitabine with docetaxel/melphalan/carboplatin (GemDMC), with preliminary high activity in refractory GCT. Given the high vascular endothelial growth factor expression in metastatic GCT and the synergy between bevacizumab and chemotherapy, we studied concurrent bevacizumab and sequential HDC using GemDMC and ifosfamide/carboplatin/etoposide (ICE) in patients with poor-risk relapsed or refractory disease...
October 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/25953445/erlotinib-associated-interstitial-lung-disease-in-advanced-pancreatic-carcinoma-a-case-report-and-literature-review
#7
REVIEW
Marianna Macerelli, Micol Mazzer, Luisa Foltran, Giovanni Gerardo Cardellino, Giuseppe Aprile
The combination of erlotinib and gemcitabine is a recognized option for patients with metastatic pancreatic cancer whose common adverse events such as skin rash, diarrhea, or fatigue are usually easily manageable. Interstitial lung disease (ILD) is a life-threatening toxicity reported in patients with non-small-cell lung cancers treated with epidermal growth factor receptor-tyrosine kinase inhibitors or gemcitabine. This side effect is extremely rare in patients with pancreatic cancer. We report fatal treatment-related ILD that occurred in a 67-year-old patient with metastatic pancreatic cancer...
July 24, 2015: Tumori
https://www.readbyqxmd.com/read/25477616/interstitial-pneumonitis-from-treatment-with-gemcitabine
#8
Brolin B Poole, Leslie A Hamilton, Megan M Brockman, Debbie C Byrd
INTRODUCTION: The use of gemcitabine may lead to numerous adverse effects ranging from mild to very severe, such as interstitial pneumonitis. The diagnosis of this complication is based on multiple laboratory findings, radiographic evidence, and high clinical suspicion. Presented is a case report of a patient who met these criteria and had onset consistent with drug-induced interstitial pneumonitis. CASE PRESENTATION: A 76-year-old White female was treated with gemcitabine for pancreatic cancer...
October 2014: Hospital Pharmacy
https://www.readbyqxmd.com/read/25414426/acute-and-delayed-toxicity-of-gemcitabine-administered-during-isolated-lung-perfusion-a-preclinical-dose-escalation-study-in-pigs
#9
Pierre-Benoit Pagès, Valentin Derangere, Olivier Bouchot, Guy Magnin, Céline Charon-Barra, François Lokiec, François Ghiringhelli, Alain Bernard
OBJECTIVES: Colorectal cancer is the third most commonly diagnosed cancer worldwide, with up to 25% of patients presenting with metastases at the time of diagnosis. Despite pulmonary metastasectomy many patients go on to develop pulmonary recurrence, which might be linked to the presence of lung micrometastases. In this setting, the adjuvant administration of high-dose chemotherapy by isolated lung perfusion (ILP) has shown encouraging results. However, the tolerance to and efficacy of modern gemcitabine (GEM)-based chemotherapy regimens during adjuvant ILP remain unknown...
August 2015: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/25209722/a-comprehensive-safety-evaluation-of-trabectedin-and-drug-drug-interactions-of-trabectedin-based-combinations
#10
REVIEW
Christian Leporini, Marinella Patanè, Francesca Saullo, Pierandrea Rende, Luca Gallelli, Eugenio Donato Di Paola, Rosa Toscano, Maria Lucia, Marco Rossi, Giovambattista De Sarro, Emilio Russo
Trabectedin (Yondelis(®)) is a potent marine-derived antineoplastic drug with high activity against various soft tissue sarcoma (STS) subtypes as monotherapy, and in combination with pegylated liposomal doxorubicin (PLD) for the treatment of patients with relapsed platinum-sensitive ovarian cancer. This article reviews the safety and pharmacokinetic profiles of trabectedin. Records were identified using predefined search criteria using electronic databases (e.g. PubMed, Cochrane Library Database of Systematic Reviews)...
December 2014: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/24722157/a-phase-i-study-of-concurrent-individualized-isotoxic-accelerated-radiotherapy-and-cisplatin-vinorelbine-cetuximab-in-patients-with-stage-iii-non-small-cell-lung-cancer
#11
Anne-Marie C Dingemans, Gerben Bootsma, Angela van Baardwijk, Bart Reymen, Rinus Wanders, Boudewijn Brans, Marco Das, Monique Hochstenbag, Arne van Belle, Ruud Houben, Philippe Lambin, Dirk de Ruysscher
BACKGROUND: In this open-label phase I study, the maximum-tolerated dose of cetuximab with concurrent chemoradiotherapy (C-CRT) in stage III non-small-cell lung cancer together with individualized, isotoxic accelerated radiotherapy (RT) was investigated. METHODS: Patients with stage III non-small-cell lung cancer, World Health Organization performance status 0-1, forced expiratory volume in 1 second more than 50%, carbon monoxide diffusing capacity more than 50%, weight loss less than 10%, and no severe comorbidity were enrolled...
May 2014: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/24155641/chemotherapy-gemcitabine-docetaxel-plus-gemcitabine-doxorubicin-or-trabectedin-in-inoperable-locally-advanced-recurrent-or-metastatic-uterine-leiomyosarcoma-a-clinical-practice-guideline
#12
A A Gupta, X Yao, S Verma, H Mackay, L Hopkins
QUESTIONS: Does chemotherapy-that is, gemcitabine, gemcitabine plus docetaxel, doxorubicin, or trabectedin-improve clinical outcomes in women with inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma (lms)? Is there a difference in the tumour response rate to chemotherapy between recurrent pelvic disease and extrapelvic metastases in the target patients? METHODS: This guideline was developed by Cancer Care Ontario's Program in Evidence-Based Care, the Sarcoma Disease Site Group (dsg), and the Gynecologic Cancer dsg...
October 2013: Current Oncology
https://www.readbyqxmd.com/read/23883337/severe-eosinophilic-pneumonia-presenting-during-gemcitabine-adjuvant-chemotherapy
#13
Tomomi Yakabe, Kenji Kitahara, Kazutoshi Komiya, Naoko Sueoka-Aragane, Shinya Kimura, Takashi Sugioka, Hirokazu Noshiro
Gemcitabine is widely accepted as the standard treatment for pancreatic cancer, but it can cause unpredictable side effects. Acute respiratory distress syndrome is a rare complication with gemcitabine, but is sometimes fatal. We describe a cured case of acute, severe gemcitabine-induced pulmonary toxicity. The patient was a 76-year-old man with pancreatic cancer who was receiving adjuvant gemcitabine chemotherapy after surgery. The patient received gemcitabine 1,000 mg/m2 on days 1, 8, and 15 for three 4-week cycles, with intervals of 1 week...
2013: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/23763798/a-multicentre-phase-ii-feasibility-study-evaluating-gemcitabine-vinorelbine-prednisolone-combination-chemotherapy-in-relapsed-refractory-hodgkin-s-lymphoma
#14
Naeem Naqi, Shaharyar Ahmad, Ijaz Shah, Javaid Khattak
OBJECTIVE: To determine the efficacy and toxicity of Gemcitabine, Vinorelbine and Prednisolone (GVP) salvage chemotherapy in relapsed / refractory Hodgkin's Lymphoma (HL). STUDY DESIGN: A phase-II non-randomized single arm study. PLACE AND DURATION OF STUDY: This study was conducted at Combined Military Hospital and Medical College Lahore, Mayo Hospital, King Edward Medical University, Lahore, Allied Hospital, Punjab Medical College, Faisalabad and Combined Military Hospital, Rawalpindi, from January 2007 to December 2007...
June 2013: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/23699639/rare-extrapulmonary-manifestations-of-gemcitabine-toxicity
#15
Edward McCann, Jerry Tran, Maria Lucarelli
SESSION TYPE: Cancer Cases IIIPRESENTED ON: Wednesday, October 24, 2012 at 11:15 AM - 12:30 PMINTRODUCTION: Gemcitabine is a pyrimidine analogue that is used to treat various malignancies. The known pulmonary toxicity from this medication includes self-limiting dyspnea, an acute hypersensitivity reaction, and an indiosyncratic reaction with pulmonary infiltrates. Pericardial effusion has not previously been described as a known side effect of gemcitabine.CASE PRESENTATION: A 62 year-old man with stage 1B pancreatic cancer was admitted for dyspnea, nonproductive cough, fevers, and pedal edema...
October 1, 2012: Chest
https://www.readbyqxmd.com/read/23615982/concurrent-chemoradiotherapy-with-low-dose-weekly-gemcitabine-in-medically-inoperable-muscle-invasive-bladder-cancer-patients
#16
B M Atasoy, F Dane, I Alsan Cetin, Z Ozgen, A Ucuncu Kefeli, R Ibrahimov, N S Turhal, U Abacioglu, L Turkeri
PURPOSE: We aimed to determine the efficacy and the toxicity of low dose weekly gemcitabine with radiation therapy in medically unfit muscle-invasive bladder cancer patients. METHODS: Twenty-six patients were included into the retrospective analysis. Weekly gemcitabine was administered 75 mg/m(2) with a median dose of 63 Gy radiation therapy. Clinical target volume was defined as the urinary bladder only in conformal treatment planning. RESULTS: Median follow-up was 51 months (range 14-118 months)...
January 2014: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/23527205/isolated-lung-perfusion-as-an-adjuvant-treatment-of-colorectal-cancer-lung-metastases-a-preclinical-study-in-a-pig-model
#17
Pierre-Benoit Pagès, Olivier Facy, Pierre Mordant, Sylvain Ladoire, Guy Magnin, Francois Lokiec, Francois Ghiringhelli, Alain Bernard
BACKGROUND: The lung is a frequent site of colorectal cancer (CRC) metastases. After surgical resection, lung metastases recurrences have been related to the presence of micrometastases, potentially accessible to a high dose chemotherapy administered via adjuvant isolated lung perfusion (ILP). We sought to determine in vitro the most efficient drug when administered to CRC cell lines during a short exposure and in vivo its immediate and delayed tolerance when administered via ILP. METHODS: First, efficacy of various cytotoxic molecules against a panel of human CRC cell lines was tested in vitro using cytotoxic assay after a 30-minute exposure...
2013: PloS One
https://www.readbyqxmd.com/read/23511559/sunitinib-in-combination-with-gemcitabine-for-advanced-solid-tumours-a-phase-i-dose-finding-study
#18
MULTICENTER STUDY
M D Michaelson, A X Zhu, D P Ryan, D F McDermott, G I Shapiro, L Tye, I Chen, P Stephenson, S Patyna, A Ruiz-Garcia, A B Schwarzberg
BACKGROUND: This phase I, dose-finding study determined the maximum tolerated dose (MTD), safety, and pharmacokinetics of sunitinib plus gemcitabine in patients with advanced solid tumours. METHODS: Two schedules with sunitinib (25-50 mg per day) and IV gemcitabine (750-1250 mg m(-2)) in escalating doses were studied. First, patients received sunitinib on a 4-weeks-on-2-weeks-off schedule (Schedule 4/2) plus gemcitabine on days 1, 8, 22, and 29. Second, patients received sunitinib on a 2-weeks-on-1-week-off schedule (Schedule 2/1) plus gemcitabine on days 1 and 8...
April 16, 2013: British Journal of Cancer
https://www.readbyqxmd.com/read/23461454/-fatal-gemcitabine-administration-related-pulmonary-toxicity
#19
M Gutiérrez García, G Flox Benítez, M Garrido Arévalo, V García Fernández, A López Martín, S Plaza Canteli
No abstract text is available yet for this article.
November 2012: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/23404815/high-resolution-computed-tomography-findings-for-patients-with-drug-induced-pulmonary-toxicity-with-special-reference-to-hypersensitivity-pneumonitis-like-patterns-in-gemcitabine-induced-cases
#20
Masaki Tamura, Takeshi Saraya, Masachika Fujiwara, Sayuki Hiraoka, Takuma Yokoyama, Kinuko Yano, Haruyuki Ishii, Junji Furuse, Tomoyuki Goya, Hajime Takizawa, Hajime Goto
BACKGROUND: Gemcitabine (GEM) is widely used as a chemotherapeutic agent. However, pulmonary toxicity has been rarely observed with GEM use. This article aims to determine the incidence and causes of drug-induced pulmonary toxicity, and to classify the high-resolution computed tomography (HRCT) findings for antitumor therapy-associated pulmonary toxicity based on characteristic patterns and pathological considerations, with a special focus on GEM-associated pulmonary toxicity (GAPT). METHODS: Medical records of all patients with drug-induced pulmonary toxicity seen at Kyorin University hospital between April 2006 and December 2011 were retrospectively reviewed...
2013: Oncologist
keyword
keyword
103192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"